Myelodysplastic Syndromes News and Research

RSS

Plant-derived compound helps restore cancer cells' sensitivity to treatment

A natural plant compound may help overcome a built-in defense that allows many cancers to resist a class of drugs designed to restore normal gene activity, according to a study by researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

2 Nov 2026

Younger mismatched donors offer new hope for blood cancer patients

Blood cancer patients who cannot find a closely matched stem cell donor may have more transplant options than previously thought.

21 Aug 2026

New study uncovers metabolic vulnerability in high-risk myelodysplastic syndromes

Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in the stem cells that drive high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer.

10 Aug 2026

New study reveals genetic drivers of inherited bone marrow failure syndrome

Inherited bone marrow failure syndrome, or IBMFS, describes a group of disorders in which inherited genetic abnormalities impair the bone marrow's ability to produce sufficient healthy blood cells.

6 Aug 2026

Unusual CD34+ dysplastic giant platelets complicate myelodysplastic syndrome diagnosis

Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by ineffective hematopoiesis, with manifestations of cytopenias in one, two, or three lineages.

28 Jun 2026

Study reveals genetic impact of Agent Orange on bone marrow cancers

More than 50 years after Agent Orange was used in Vietnam, a new national study published online ahead of print in Blood Advances highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes (MDS), a group of bone marrow cancers that can progress to acute leukemia.

23 Mar 2026

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

Multidimensional regulation of stem cell fate by the cohesin complex

Conventional studies on stem cell fates are primarily focused on transcription factors, with the limited consideration for 3D genome architecture.

10 Oct 2025

Many patients with high-risk myelodysplastic syndromes do not receive guideline-recommended treatment

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia.

6 Aug 2025

Taurine identified as a key regulator of myeloid cancers

A new scientific study identified taurine, which is made naturally in the body and consumed through some foods, as a key regulator of myeloid cancers such as leukemia, according to a paper published in the journal Nature.

14 May 2025

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

9 Mar 2025

Advancements in molecular diagnostics for hematopoietic and lymphocytic neoplasms

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

27 Feb 2025

Huntsman Cancer Institute joins innovative clinical trials program for blood cancers

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials program designed to match patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with a clinical trial specifically designed for the genetic signature of their disease.

17 Dec 2024

WashU Medicine receives $10.8 million grant to advance blood cancer research

Continuing its role as a leader in leukemia research, Washington University School of Medicine in St. Louis has been awarded a five-year, $10.8 million grant to further its exceptional programs in leukemia and other blood cancers.

16 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

Smoking linked to increased genetic mutations in myelodysplastic syndromes

Smokers with myelodysplastic syndromes (MDS) or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows.

9 Dec 2024

Advances in neutropenia research could pave the way for better treatments

Neutropenia is a condition in which there are not enough neutrophils, a type of white blood cell, in the blood.

5 Nov 2024

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

23 Oct 2024

NIH launches precision medicine trial to test new treatments for myeloid cancers

The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

23 Oct 2024

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

23 Oct 2024

Myelodysplastic Syndromes News and Research

Plant-derived compound helps restore cancer cells' sensitivity to treatment

Younger mismatched donors offer new hope for blood cancer patients

New study uncovers metabolic vulnerability in high-risk myelodysplastic syndromes

New study reveals genetic drivers of inherited bone marrow failure syndrome

Unusual CD34+ dysplastic giant platelets complicate myelodysplastic syndrome diagnosis

Study reveals genetic impact of Agent Orange on bone marrow cancers

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

Multidimensional regulation of stem cell fate by the cohesin complex

Many patients with high-risk myelodysplastic syndromes do not receive guideline-recommended treatment

Taurine identified as a key regulator of myeloid cancers

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Advancements in molecular diagnostics for hematopoietic and lymphocytic neoplasms

Huntsman Cancer Institute joins innovative clinical trials program for blood cancers

WashU Medicine receives $10.8 million grant to advance blood cancer research

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Smoking linked to increased genetic mutations in myelodysplastic syndromes

Advances in neutropenia research could pave the way for better treatments

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

NIH launches precision medicine trial to test new treatments for myeloid cancers

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News